NASDAQ
PROK
Last Price
US $2.03
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
ProKidney Corp. cash flow to debt ratio of -2.98K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
ProKidney Corp.'s free cash flow has increased -13.18% from $-155.86M last year to $-135.31M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
ProKidney Corp.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
ProKidney Corp.'s debt has increased relative to shareholder equity from -0.00 last year to 0.00 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
ProKidney Corp. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
ProKidney Corp. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
ProKidney Corp.'s profit margin has increased (-89.54%) in the last year from -80.51K% to -8.42K%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
ProKidney Corp.'s short-term assets of $280.68M exceed its short-term liabilities of $30.74M
Decreasing performance - ROA.
ProKidney Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
ProKidney Corp.'s return on equity of 7.40%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
ProKidney Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
ProKidney Corp. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
ProKidney Corp. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
ProKidney Corp. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
ProKidney Corp.'s yearly earnings has decreased 12.75% since last year from $-61.19M to $-68.99M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
ProKidney Corp.'s yearly revenue has increased 1.07K% since last year from $76.00K to $893.00K, signaling increasing performance
Decreasing performance - ROIC.
ROIC -54.77% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
ProKidney Corp. has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
ProKidney Corp. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
ProKidney Corp. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
ProKidney Corp. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
ProKidney Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
ProKidney Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
ProKidney Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
ProKidney Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
ProKidney Corp. has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
ProKidney Corp. has a price-to-sales ratio of 692.18x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
7.40%
Return on equity
ROIC: -54.77%
Valuation History
-3.3X
Price to Earnings
EV/EBITDA: -3.4X
Cash flow
Profit margin
-29.02%
(FY vs FY)
Cash flow Y/Y
-25.70%
(FY vs FY)
Fair Value
Market $2.03
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.